Cyanvac LLC is developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. Our vaccines have the potential to block the transmission of viral infections and reduce their spread. Our PIV5-based vaccines will be easy to administer, easy to transport, and easy to manufacture.